Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 510

1.

Synergistic enhancement of cellular uptake with CD44-expressing malignant pleural mesothelioma by combining cationic liposome and hyaluronic acid-lipid conjugate.

Sakurai Y, Kato A, Hida Y, Hamada J, Maishi N, Hida K, Harashima H.

J Pharm Sci. 2019 Jun 20. pii: S0022-3549(19)30382-X. doi: 10.1016/j.xphs.2019.06.012. [Epub ahead of print]

PMID:
31229434
2.

A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes.

Santiwarangkool S, Akita H, Khalil IA, Abd Elwakil MM, Sato Y, Kusumoto K, Harashima H.

J Control Release. 2019 Jun 8;307:55-63. doi: 10.1016/j.jconrel.2019.06.009. [Epub ahead of print]

PMID:
31185231
3.

Enhanced autophagy induction via the mitochondrial delivery of methylated β-cyclodextrin-threaded polyrotaxanes using a MITO-Porter.

Yamada Y, Daikuhara S, Tamura A, Nishida K, Yui N, Harashima H.

Chem Commun (Camb). 2019 Jun 25;55(50):7203-7206. doi: 10.1039/c9cc03272j. Epub 2019 Jun 5.

PMID:
31165120
4.

The Cdk1/Cdk2 homolog CDKA;1 controls the recombination landscape in Arabidopsis.

Wijnker E, Harashima H, Müller K, Parra-Nuñez P, de Snoo CB, van de Belt J, Dissmeyer N, Bayer M, Pradillo M, Schnittger A.

Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12534-12539. doi: 10.1073/pnas.1820753116. Epub 2019 Jun 4.

5.

The Use of a Microfluidic Device to Encapsulate a Poorly Water-Soluble Drug CoQ10 in Lipid Nanoparticles and an Attempt to Regulate Intracellular Trafficking to Reach Mitochondria.

Hibino M, Yamada Y, Fujishita N, Sato Y, Maeki M, Tokeshi M, Harashima H.

J Pharm Sci. 2019 Apr 5. pii: S0022-3549(19)30214-X. doi: 10.1016/j.xphs.2019.04.001. [Epub ahead of print]

PMID:
30959057
6.

Cardiomyopathy in children with mitochondrial disease: Prognosis and genetic background.

Imai-Okazaki A, Kishita Y, Kohda M, Mizuno Y, Fushimi T, Matsunaga A, Yatsuka Y, Hirata T, Harashima H, Takeda A, Nakaya A, Sakata Y, Kogaki S, Ohtake A, Murayama K, Okazaki Y.

Int J Cardiol. 2019 Mar 15;279:115-121. doi: 10.1016/j.ijcard.2019.01.017. Epub 2019 Jan 5.

PMID:
30642647
7.

Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.

Sato Y, Hashiba K, Sasaki K, Maeki M, Tokeshi M, Harashima H.

J Control Release. 2019 Feb 10;295:140-152. doi: 10.1016/j.jconrel.2019.01.001. Epub 2019 Jan 2.

PMID:
30610950
8.

Mitochondrial ribosomal protein PTCD3 mutations cause oxidative phosphorylation defects with Leigh syndrome.

Borna NN, Kishita Y, Kohda M, Lim SC, Shimura M, Wu Y, Mogushi K, Yatsuka Y, Harashima H, Hisatomi Y, Fushimi T, Ichimoto K, Murayama K, Ohtake A, Okazaki Y.

Neurogenetics. 2019 Mar;20(1):9-25. doi: 10.1007/s10048-018-0561-9. Epub 2019 Jan 3.

PMID:
30607703
9.

Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting.

Shobaki N, Sato Y, Harashima H.

Int J Nanomedicine. 2018 Dec 10;13:8395-8410. doi: 10.2147/IJN.S188016. eCollection 2018.

10.

The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds.

Tanaka H, Watanabe A, Konishi M, Nakai Y, Yoshioka H, Ohkawara T, Takeda H, Harashima H, Akita H.

Heliyon. 2018 Dec 3;4(12):e00959. doi: 10.1016/j.heliyon.2018.e00959. eCollection 2018 Dec.

11.

Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis.

Sakurai Y, Hada T, Kato A, Hagino Y, Mizumura W, Harashima H.

Mol Ther Oncolytics. 2018 Oct 30;11:102-108. doi: 10.1016/j.omto.2018.10.004. eCollection 2018 Dec 21.

12.

Genome-wide identification of RETINOBLASTOMA RELATED 1 binding sites in Arabidopsis reveals novel DNA damage regulators.

Bouyer D, Heese M, Chen P, Harashima H, Roudier F, Grüttner C, Schnittger A.

PLoS Genet. 2018 Nov 30;14(11):e1007797. doi: 10.1371/journal.pgen.1007797. eCollection 2018 Nov.

13.

Critical parameters dictating efficiency of membrane-mediated drug transfer using nanoparticles.

Abbasi S, Kajimoto K, Harashima H.

Int J Pharm. 2018 Dec 20;553(1-2):398-407. doi: 10.1016/j.ijpharm.2018.10.042. Epub 2018 Oct 26.

PMID:
30393168
14.

Application of BCG-CWS as a Systemic Adjuvant by Using Nanoparticulation Technology.

Masuda H, Nakamura T, Noma Y, Harashima H.

Mol Pharm. 2018 Dec 3;15(12):5762-5771. doi: 10.1021/acs.molpharmaceut.8b00919. Epub 2018 Nov 8.

PMID:
30380885
15.

Optimization of siRNA delivery to target sites: issues and future directions.

Khalil IA, Yamada Y, Harashima H.

Expert Opin Drug Deliv. 2018 Nov;15(11):1053-1065. doi: 10.1080/17425247.2018.1520836. Epub 2018 Sep 25. Review.

PMID:
30198792
16.

DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.

Kawai M, Nakamura T, Miura N, Maeta M, Tanaka H, Ueda K, Higashi K, Moribe K, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Nanomedicine. 2018 Nov;14(8):2587-2597. doi: 10.1016/j.nano.2018.08.006. Epub 2018 Aug 29.

PMID:
30170077
17.

The use of cardiac progenitor cells for transplantation in congenital heart disease and an innovative strategy for activating mitochondrial function in such cells.

Abe J, Yamada Y, Harashima H.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2119-S2121. doi: 10.21037/jtd.2018.06.76. No abstract available.

18.

Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.

Sato Y, Matsui H, Sato R, Harashima H.

J Control Release. 2018 Aug 28;284:179-187. doi: 10.1016/j.jconrel.2018.06.017. Epub 2018 Jun 21.

PMID:
29936118
19.

Haptic-based perception-empathy biofeedback system for balance rehabilitation in patients with chronic stroke: Concepts and initial feasibility study.

Yasuda K, Saichi K, Kaibuki N, Harashima H, Iwata H.

Gait Posture. 2018 May;62:484-489. doi: 10.1016/j.gaitpost.2018.04.013. Epub 2018 Apr 14.

PMID:
29677663
20.

A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug.

Togashi R, Tanaka H, Nakamura S, Yokota H, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

J Control Release. 2018 Jun 10;279:262-270. doi: 10.1016/j.jconrel.2018.04.022. Epub 2018 Apr 17.

PMID:
29673647
21.

Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.

Nakamura T, Yamada K, Fujiwara Y, Sato Y, Harashima H.

Mol Pharm. 2018 Jun 4;15(6):2142-2150. doi: 10.1021/acs.molpharmaceut.7b01166. Epub 2018 Apr 30.

PMID:
29668291
22.

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration.

Tanaka H, Nakatani T, Furihata T, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Mol Pharm. 2018 May 7;15(5):2060-2067. doi: 10.1021/acs.molpharmaceut.7b01084. Epub 2018 Apr 11.

PMID:
29638135
23.

Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems.

Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M.

Adv Drug Deliv Rev. 2018 Mar 15;128:84-100. doi: 10.1016/j.addr.2018.03.008. Epub 2018 Mar 19. Review.

PMID:
29567396
24.

Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles.

Khalil IA, Kimura S, Sato Y, Harashima H.

J Control Release. 2018 Apr 10;275:107-116. doi: 10.1016/j.jconrel.2018.02.016. Epub 2018 Feb 13.

25.

Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.

Ishikawa T, Somiya K, Munechika R, Harashima H, Yamada Y.

J Control Release. 2018 Mar 28;274:109-117. doi: 10.1016/j.jconrel.2018.02.005. Epub 2018 Feb 3.

26.

An efficient PEGylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide.

Khalil IA, Harashima H.

Int J Pharm. 2018 Mar 1;538(1-2):179-187. doi: 10.1016/j.ijpharm.2018.01.007. Epub 2018 Jan 16.

27.

Barth Syndrome: Different Approaches to Diagnosis.

Imai-Okazaki A, Kishita Y, Kohda M, Yatsuka Y, Hirata T, Mizuno Y, Harashima H, Hirono K, Ichida F, Noguchi A, Yoshida M, Tokorodani C, Nishiuchi R, Takeda A, Nakaya A, Sakata Y, Murayama K, Ohtake A, Okazaki Y.

J Pediatr. 2018 Feb;193:256-260. doi: 10.1016/j.jpeds.2017.09.075. Epub 2017 Dec 15.

PMID:
29249525
28.

Packaging of the Coenzyme Q10 into a Liposome for Mitochondrial Delivery and the Intracellular Observation in Patient Derived Mitochondrial Disease Cells.

Yamada Y, Burger L, Kawamura E, Harashima H.

Biol Pharm Bull. 2017;40(12):2183-2190. doi: 10.1248/bpb.b17-00609.

29.

Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers.

Maeki M, Fujishima Y, Sato Y, Yasui T, Kaji N, Ishida A, Tani H, Baba Y, Harashima H, Tokeshi M.

PLoS One. 2017 Nov 28;12(11):e0187962. doi: 10.1371/journal.pone.0187962. eCollection 2017.

30.

Optical control of mitochondrial reductive reactions in living cells using an electron donor-acceptor linked molecule.

Takano Y, Munechika R, Biju V, Harashima H, Imahori H, Yamada Y.

Nanoscale. 2017 Dec 7;9(47):18690-18698. doi: 10.1039/c7nr06310e.

31.

Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium.

Abe J, Yamada Y, Takeda A, Harashima H.

J Control Release. 2018 Jan 10;269:177-188. doi: 10.1016/j.jconrel.2017.11.024. Epub 2017 Nov 14.

PMID:
29146241
32.

Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.

Yamamoto S, Sakurai Y, Harashima H.

Int J Pharm. 2018 Jan 30;536(1):42-49. doi: 10.1016/j.ijpharm.2017.11.010. Epub 2017 Nov 7.

33.

Integration of nano drug-delivery system with cancer immunotherapy.

Nakamura T, Harashima H.

Ther Deliv. 2017 Nov;8(11):987-1000. doi: 10.4155/tde-2017-0071. Review.

PMID:
29061103
34.

Preparation of envelope-type lipid nanoparticles containing gold nanorods for photothermal cancer therapy.

Paraiso WKD, Tanaka H, Sato Y, Shirane D, Suzuki N, Ogra Y, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Colloids Surf B Biointerfaces. 2017 Dec 1;160:715-723. doi: 10.1016/j.colsurfb.2017.10.027. Epub 2017 Oct 9.

PMID:
29035819
35.

In Vivo Transgene Expression in the Pancreas by the Intraductal Injection of Naked Plasmid DNA.

Yamada Y, Tabata M, Abe J, Nomura M, Harashima H.

J Pharm Sci. 2018 Feb;107(2):647-653. doi: 10.1016/j.xphs.2017.09.021. Epub 2017 Oct 6.

36.

Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.

Sato Y, Matsui H, Yamamoto N, Sato R, Munakata T, Kohara M, Harashima H.

J Control Release. 2017 Nov 28;266:216-225. doi: 10.1016/j.jconrel.2017.09.044. Epub 2017 Oct 3.

PMID:
28986168
37.

Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling.

Nichols JW, Sakurai Y, Harashima H, Bae YH.

J Control Release. 2017 Dec 10;267:31-46. doi: 10.1016/j.jconrel.2017.08.003. Epub 2017 Aug 12. Review.

PMID:
28807683
38.

Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.

Sakurai Y, Mizumura W, Murata M, Hada T, Yamamoto S, Ito K, Iwasaki K, Katoh T, Goto Y, Takagi A, Kohara M, Suga H, Harashima H.

Mol Pharm. 2017 Oct 2;14(10):3290-3298. doi: 10.1021/acs.molpharmaceut.7b00362. Epub 2017 Aug 25.

PMID:
28789523
39.

pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.

Hashiba K, Sato Y, Harashima H.

J Control Release. 2017 Sep 28;262:239-246. doi: 10.1016/j.jconrel.2017.07.046. Epub 2017 Aug 1.

40.

Size-Dependency of the Surface Ligand Density of Liposomes Prepared by Post-insertion.

Lee SH, Sato Y, Hyodo M, Harashima H.

Biol Pharm Bull. 2017;40(7):1002-1009. doi: 10.1248/bpb.b16-00990.

41.

Identification and Evaluation of the Minimum Unit of a KALA Peptide Required for Gene Delivery and Immune Activation.

Miura N, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

J Pharm Sci. 2017 Oct;106(10):3113-3119. doi: 10.1016/j.xphs.2017.05.014. Epub 2017 May 20.

42.

Validation of the use of an artificial mitochondrial reporter DNA vector containing a Cytomegalovirus promoter for mitochondrial transgene expression.

Yamada Y, Ishikawa T, Harashima H.

Biomaterials. 2017 Aug;136:56-66. doi: 10.1016/j.biomaterials.2017.05.016. Epub 2017 May 10.

PMID:
28521201
43.

PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Encapsulated siRNA.

Santiwarangkool S, Akita H, Nakatani T, Kusumoto K, Kimura H, Suzuki M, Nishimura M, Sato Y, Harashima H.

J Pharm Sci. 2017 Sep;106(9):2420-2427. doi: 10.1016/j.xphs.2017.04.075. Epub 2017 May 5.

PMID:
28483420
44.

Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.

Yamada Y, Munechika R, Kawamura E, Sakurai Y, Sato Y, Harashima H.

J Pharm Sci. 2017 Sep;106(9):2428-2437. doi: 10.1016/j.xphs.2017.04.058. Epub 2017 May 3.

PMID:
28478130
45.

RETINOBLASTOMA RELATED1 mediates germline entry in Arabidopsis.

Zhao X, Bramsiepe J, Van Durme M, Komaki S, Prusicki MA, Maruyama D, Forner J, Medzihradszky A, Wijnker E, Harashima H, Lu Y, Schmidt A, Guthörl D, Logroño RS, Guan Y, Pochon G, Grossniklaus U, Laux T, Higashiyama T, Lohmann JU, Nowack MK, Schnittger A.

Science. 2017 Apr 28;356(6336). pii: eaaf6532. doi: 10.1126/science.aaf6532.

PMID:
28450583
46.

The effect of a haptic biofeedback system on postural control in patients with stroke: An experimental pilot study.

Yasuda K, Kaibuki N, Harashima H, Iwata H.

Somatosens Mot Res. 2017 Jun;34(2):65-71. doi: 10.1080/08990220.2017.1292236. Epub 2017 Apr 3.

PMID:
28372470
47.

The retinoblastoma homolog RBR1 mediates localization of the repair protein RAD51 to DNA lesions in Arabidopsis.

Biedermann S, Harashima H, Chen P, Heese M, Bouyer D, Sofroni K, Schnittger A.

EMBO J. 2017 May 2;36(9):1279-1297. doi: 10.15252/embj.201694571. Epub 2017 Mar 20.

48.

Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.

Miura N, Akita H, Tateshita N, Nakamura T, Harashima H.

Mol Ther. 2017 Apr 5;25(4):1003-1013. doi: 10.1016/j.ymthe.2017.01.020. Epub 2017 Feb 22.

49.

Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.

Yamamoto S, Kato A, Sakurai Y, Hada T, Harashima H.

J Control Release. 2017 Apr 10;251:1-10. doi: 10.1016/j.jconrel.2017.02.010. Epub 2017 Feb 10.

50.

Scalable preparation of poly(ethylene glycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration.

Sakurai Y, Hada T, Harashima H.

J Biomater Sci Polym Ed. 2017 Jul - Aug;28(10-12):1086-1096. doi: 10.1080/09205063.2017.1291297. Epub 2017 Feb 10.

Supplemental Content

Loading ...
Support Center